June 14, 2017

UAFRS vs As-Reported Weekly Highlights for June 14, 2017


Each week, Valens focuses on several companies that were analyzed in the prior week, where material distortions caused by as-reported GAAP accounting need to be corrected to understand a company’s economic fundamentals.

Company Specific Highlights & Insights

Teva Pharmaceutical Industries Limited (TEVA)
R&D Expense Distortion

Palo Alto Networks, Inc. (PANW)
Stock Option Expense Distortion

Valeant Pharmaceuticals International, Inc. (VRX)
Gross Cash Flow Acquisition Adjustment

Click here to view the report in its entirety.

Enter your name and email address below so that we can keep you apprised on future Valens vs As-Reported Weekly Highlights.